Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Remicade Biosimilar Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Remicade Biosimilar Industry
  • 1.7 COVID-19 Impact: Remicade Biosimilar Market Trends

    • 2 Global Remicade Biosimilar Quarterly Market Size Analysis

    • 2.1 Remicade Biosimilar Business Impact Assessment - COVID-19
      • 2.1.1 Global Remicade Biosimilar Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Remicade Biosimilar Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Remicade Biosimilar Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Remicade Biosimilar Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Remicade Biosimilar Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Remicade Biosimilar Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Remicade Biosimilar Market
    • 3.5 Key Manufacturers Remicade Biosimilar Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Remicade Biosimilar Segments, By Type

    • 4.1 Introduction
      • 1.4.1 100mg/10ml
      • 1.4.2 500mg/50ml
    • 4.2 By Type, Global Remicade Biosimilar Market Size, 2019-2021
      • 4.2.1 By Type, Global Remicade Biosimilar Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Remicade Biosimilar Price, 2020-2021

    5 Impact of Covid-19 on Remicade Biosimilar Segments, By Application

    • 5.1 Overview
      • 5.5.1 Blood Disorders
      • 5.5.2 Oncology Diseases
    • 5.2 By Application, Global Remicade Biosimilar Market Size, 2019-2021
      • 5.2.1 By Application, Global Remicade Biosimilar Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Remicade Biosimilar Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Synthon Pharmaceuticals
      • 7.1.1 Synthon Pharmaceuticals Business Overview
      • 7.1.2 Synthon Pharmaceuticals Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.1.3 Synthon Pharmaceuticals Remicade Biosimilar Product Introduction
      • 7.1.4 Synthon Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.2 LG Life Sciences
      • 7.2.1 LG Life Sciences Business Overview
      • 7.2.2 LG Life Sciences Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.2.3 LG Life Sciences Remicade Biosimilar Product Introduction
      • 7.2.4 LG Life Sciences Response to COVID-19 and Related Developments
    • 7.3 Novartis (Sandoz)
      • 7.3.1 Novartis (Sandoz) Business Overview
      • 7.3.2 Novartis (Sandoz) Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.3.3 Novartis (Sandoz) Remicade Biosimilar Product Introduction
      • 7.3.4 Novartis (Sandoz) Response to COVID-19 and Related Developments
    • 7.4 Celltrion
      • 7.4.1 Celltrion Business Overview
      • 7.4.2 Celltrion Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.4.3 Celltrion Remicade Biosimilar Product Introduction
      • 7.4.4 Celltrion Response to COVID-19 and Related Developments
    • 7.5 Biocon
      • 7.5.1 Biocon Business Overview
      • 7.5.2 Biocon Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.5.3 Biocon Remicade Biosimilar Product Introduction
      • 7.5.4 Biocon Response to COVID-19 and Related Developments
    • 7.6 Hospira
      • 7.6.1 Hospira Business Overview
      • 7.6.2 Hospira Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.6.3 Hospira Remicade Biosimilar Product Introduction
      • 7.6.4 Hospira Response to COVID-19 and Related Developments
    • 7.7 Merck Serono (Merck Group)
      • 7.7.1 Merck Serono (Merck Group) Business Overview
      • 7.7.2 Merck Serono (Merck Group) Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.7.3 Merck Serono (Merck Group) Remicade Biosimilar Product Introduction
      • 7.7.4 Merck Serono (Merck Group) Response to COVID-19 and Related Developments
    • 7.8 Biogen idec Inc.
      • 7.8.1 Biogen idec Inc. Business Overview
      • 7.8.2 Biogen idec Inc. Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.8.3 Biogen idec Inc. Remicade Biosimilar Product Introduction
      • 7.8.4 Biogen idec Inc. Response to COVID-19 and Related Developments
    • 7.9 Genentech (Roche Group)
      • 7.9.1 Genentech (Roche Group) Business Overview
      • 7.9.2 Genentech (Roche Group) Remicade Biosimilar Quarterly Production and Revenue, 2020
      • 7.9.3 Genentech (Roche Group) Remicade Biosimilar Product Introduction
      • 7.9.4 Genentech (Roche Group) Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Remicade Biosimilar Supply Chain Analysis
      • 8.1.1 Remicade Biosimilar Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Remicade Biosimilar Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Remicade Biosimilar Distribution Channels
      • 8.2.2 Covid-19 Impact on Remicade Biosimilar Distribution Channels
      • 8.2.3 Remicade Biosimilar Distributors
    • 8.3 Remicade Biosimilar Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Remicade Biosimilar, including the following market information:
      Global Remicade Biosimilar Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Remicade Biosimilar Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Remicade Biosimilar Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Remicade Biosimilar Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)

      Key market players
      Major competitors identified in this market include Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec Inc., Genentech (Roche Group), etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      100mg/10ml
      500mg/50ml

      Based on the Application:
      Blood Disorders
      Oncology Diseases

      Buy now